Sit Investment Associates Inc. lowered its position in Pfizer, Inc. (NYSE:PFE) by 10.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,050,665 shares of the biopharmaceutical company’s stock after selling 118,345 shares during the period. Pfizer comprises about 0.9% of Sit Investment Associates Inc.’s investment portfolio, making the stock its 24th largest position. Sit Investment Associates Inc.’s holdings in Pfizer were worth $35,943,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of PFE. Asset Planning Services Ltd. boosted its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares in the last quarter. Orrstown Financial Services Inc. boosted its position in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares in the last quarter. Cable Hill Partners LLC boosted its position in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares in the last quarter. D Orazio & Associates Inc. boosted its position in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares in the last quarter. Finally, Acropolis Investment Management LLC boosted its position in Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 69.95% of the company’s stock.
Shares of Pfizer, Inc. (NYSE:PFE) traded up 0.287% during mid-day trading on Monday, hitting $33.245. The stock had a trading volume of 4,455,601 shares. The stock has a 50 day moving average of $33.36 and a 200-day moving average of $33.24. The stock has a market capitalization of $198.40 billion, a P/E ratio of 27.984 and a beta of 1.01. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $37.39.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $12.78 billion for the quarter, compared to analysts’ expectations of $13.09 billion. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. Pfizer’s revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 EPS. On average, equities research analysts predict that Pfizer, Inc. will post $2.55 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a $0.32 dividend. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.86%. Pfizer’s dividend payout ratio (DPR) is presently 108.48%.
ILLEGAL ACTIVITY WARNING: This piece was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/07/31/pfizer-inc-pfe-stake-cut-by-sit-investment-associates-inc-updated.html.
A number of brokerages have issued reports on PFE. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and cut their target price for the company from $38.00 to $31.00 in a research report on Tuesday, May 16th. Barclays PLC reissued a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. Credit Suisse Group lowered Pfizer from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $38.00 to $36.00 in a research report on Thursday, July 20th. Cowen and Company set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research report on Monday, July 10th. Finally, Jefferies Group LLC reissued a “neutral” rating and set a $34.00 price target on shares of Pfizer in a research report on Friday, June 16th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and ten have given a buy rating to the stock. Pfizer has a consensus rating of “Hold” and an average target price of $37.68.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
